Clinical trials: Dermatitis Atopic
Atopic Dermatitis
Abrocitinib Dose Tapering in Patients With Atopic Dermatitis
This prospective, multicenter study aims to evaluate whether patients with moderate-to-severe atopic dermatitis who achieve optimal disease control during treatment with abrocitinib 200 mg once daily can maintain disease control…
- Trial name
- MODA-AD (NCT07848074)
- Testing
- Abrocitinib
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Dermatitis, Atopic
Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis
The primary objective of the study was to evaluate the efficacy of 611 in Chinese adults with moderate to severe atopic dermatitis.
- Trial name
- NCT06173284
- Testing
- 611
- Where
- 4 sites in China
- Volunteers
- 519 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Atopic Dermatitis
Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis
The purpose of this study is to assess the efficacy of short-term treatment with fluocinonide cream 0.1% (Vanos®) in the treatment of atopic dermatitis (AD).
- Trial name
- NCT01469767
- Testing
- Fluocinonide cream
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University
Dermatitis, Atopic
Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream
Welichem Biotech has developed a small molecule drug candidate, WBI-1001, that selectively targets the pathogenic features of inflammatory skin diseases, including atopic dermatitis (a form of eczema).The purpose of this clinical…
- Trial name
- NCT01098734
- Testing
- WBI-1001
- Where
- 5 sites in Canada
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Welichem Biotech Inc.
Atopic Dermatitis
Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation
The clinical efficacy of tralokinumab has been demonstrated in the treatment of AD; its MOA however remains insufficiently understood.
- Trial name
- TRALIS (NCT05378698)
- Testing
- Application of Tralokinumab
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Atopic Dermatitis
Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis
This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, pharmacokinetics(PK), pharmacodynamics(PD) and immunogenicity of CM310 in children patients with…
- Trial name
- NCT06277765
- Testing
- CM310
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis
A Phase I Study of HY209 Gel in Healthy Male Volunteers for Atopic Dermatitis
A randomized, double-blind, placebo-controlled single and multiple dosing, dose escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of HY209 gel after transdermal administration in…
- Trial name
- Shaperon (NCT03492398)
- Testing
- HY209
- Where
- South Korea
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Shaperon
Milk and/or Peanut Allergy
Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis
Background: Atopic dermatitis (AD), also called eczema, makes skin dry, red, and itchy. People with AD are more likely to get a food allergy than people without AD.
- Trial name
- NCT03835767
- Testing
- Peanut powder and Oat flour
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis (Eczema)
Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema
This is a research study where all subjects will receive study medication to understand how the body processes the study medication, and to determine the PK, safety and efficacy of ARQ-151 cream 0.15% or 0.05% in adolescent and…
- Trial name
- NCT04156191
- Testing
- ARQ-151 cream 0.15%, ARQ-151 cream 0.05%
- Where
- 10 sites in United States
- Volunteers
- 101 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Atopic Dermatitis
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis
- Trial name
- NCT06775860
- Testing
- ICP-332 Tablets
- Where
- 62 sites in China
- Volunteers
- 552 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Atopic Dermatitis (AD)
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis
This study is an Ic/II phase clinical trial conducted in Chinese subjects with moderate to severe atopic dermatitis. The phase Ic study is a randomized, open label, parallel group design, mainly evaluating the safety and…
- Trial name
- NCT06931990
- Testing
- LT-002-158 tablets
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Atopic Diathesis, Eczema-prone Skin
Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 5 Days of Use on Subjects With Atopic Dermatitis
The aim of this study is to compare the efficacy and tolerability and of a cosmetic product to one that is already available on the market (benchmark product).
- Trial name
- NCT05807113
- Testing
- Atopi intensive care BNO 3731, Benchmark product
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Bionorica SE
Atopic Dermatitis, Psoriasis
Molecular and Cellular Characterization of Spongiotic Dermatitis
Spongiotic dermatitis is the histopathologic diagnosis commonly issued by dermatopathologists that encompasses atopic dermatitis, contact dermatitis, and other forms of eczematous dermatitis.
- Conditions
- Atopic Dermatitis, Psoriasis, Contact Dermatitis
- Trial name
- Spongiotic (NCT00371163)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Eczema, Atopic Dermatitis
A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis
An open-label, multicenter, Phase Ib study of B244 delivered as a topical spray to assess safety in pediatric subjects aged 2 to 17 years with atopic dermatitis Condition or disease Intervention/treatment Phase Atopic Dermatitis…
- Trial name
- NCT03775434
- Testing
- Experimental: B244
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- AOBiome LLC
Atopic Dermatitis
Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis
This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, PK, PD and immumogenicity of GR1802 injection in comparison to placebo in patients with atopic dermatitis.
- Trial name
- NCT06216392
- Testing
- GR1802 injection
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Dermatitis, Atopic
A Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other Therapies
The purpose of this observational study is to learn about the effects of the study medicine (called abrocitinib) for the treatment of severe atopic dermatitis in people that were moved from previous novel therapies, known as…
- Trial name
- NCT07887867
- Testing
- abrocitinib
- Volunteers
- 120 people
- Sponsor
- Pfizer
Atopic Dermatitis
Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis
The purpose of this study is to evaluate dose response, safety, tolerability and efficacy of 2.5% and 5% cis-UCA in comparison to placebo and active comparator in the treatment of adult patients with moderate or severe chronic…
- Trial name
- NCT01320579
- Testing
- Cis-UCA 2.5% emulsion cream, Cis-UCA 5% emulsion cream, Protopic® 0.1% ointment
- Where
- 7 sites in Finland
- Volunteers
- 159 people
- Sponsor
- BioCis Pharma Ltd
Adult Atopic Dermatitis
Probiotics in Adults: do They Improve Atopic Dermatitis?
Probiotics are suggested to have beneficial effects in atopic dermatitis (AD) treatment and prevention but their precise role is not yet clear.
- Trial name
- NCT01500941
- Testing
- probiotics, maltodextrin
- Where
- Italy
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- ASST Fatebenefratelli Sacco
Atopic Dermatitis Eczema
Study in Subjects With Moderate Atopic Dermatitis
This is a Phase 2, randomized, double-blind, vehicle-controlled, parallel-group study to evaluate the safety and efficacy of ALX-101 Gel 5% and a matching ALX-101 Gel Vehicle when applied topically twice daily for 56 days in…
- Trial name
- NCT03859986
- Testing
- ALX-101 Gel Vehicle, ALX-101 Gel 5%
- Where
- 22 sites in United States, Canada
- Volunteers
- 124 people
- Sponsor
- Ralexar Therapeutics, Inc.
Atopic Dermatitis
Vitamin D in Egyptian Children With Atopic Dermatitis
There is an emergent evidence demonstrating the role of Vitamin D deficiency in eczema. Vitamin D supplementation with standard treatment yielded positive clinical outcomes for children and adolescents with mild and moderate AD…
- Trial name
- NCT04468711
- Testing
- Vitamin D
- Where
- Egypt
- Volunteers
- 92 people
- Sponsor
- National Hepatology & Tropical Medicine Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.